Qiagen N.V. (NYSE:QGEN) Given Consensus Recommendation of “Hold” by Analysts

Shares of Qiagen N.V. (NYSE:QGEN) have earned an average rating of “Hold” from the nine ratings firms that are presently covering the company, MarketBeat.com reports. Seven investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $52.8421.

QGEN has been the topic of several recent analyst reports. Barclays restated an “overweight” rating and set a $57.89 price objective (up previously from $55.79) on shares of Qiagen in a report on Monday, December 15th. Citigroup lowered shares of Qiagen from a “buy” rating to a “neutral” rating and cut their price target for the company from $57.89 to $52.63 in a report on Thursday, December 11th. Wall Street Zen lowered shares of Qiagen from a “buy” rating to a “hold” rating in a research note on Saturday, January 10th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Qiagen in a research note on Monday, December 29th.

Institutional Investors Weigh In On Qiagen

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in shares of Qiagen by 1.9% in the 3rd quarter. Vanguard Group Inc. now owns 9,424,809 shares of the company’s stock valued at $420,401,000 after purchasing an additional 172,062 shares during the period. Amundi increased its stake in Qiagen by 4.4% in the 3rd quarter. Amundi now owns 4,290,273 shares of the company’s stock valued at $201,471,000 after buying an additional 181,509 shares during the period. Boston Partners purchased a new stake in Qiagen in the 3rd quarter worth approximately $179,450,000. Norges Bank acquired a new stake in shares of Qiagen during the 2nd quarter valued at $158,728,000. Finally, Allspring Global Investments Holdings LLC grew its holdings in shares of Qiagen by 10.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 3,164,805 shares of the company’s stock valued at $143,018,000 after acquiring an additional 290,449 shares in the last quarter. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Qiagen Trading Down 1.5%

Shares of NYSE:QGEN opened at $47.64 on Monday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 2.30 and a current ratio of 2.60. The stock has a market capitalization of $10.06 billion, a price-to-earnings ratio of 24.60, a PEG ratio of 2.19 and a beta of 0.66. Qiagen has a 1-year low of $39.61 and a 1-year high of $54.61. The company has a 50 day moving average price of $48.17 and a 200 day moving average price of $49.40.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.61 by $0.03. The company had revenue of $532.58 million during the quarter, compared to the consensus estimate of $525.68 million. Qiagen had a return on equity of 14.80% and a net margin of 19.58%.The company’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.60 EPS. On average, research analysts anticipate that Qiagen will post 2.26 EPS for the current fiscal year.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.